Trial NCT04864561
Publication Lazarus, SSRN, 2022
Primary outcome on the report: 1) GMT of S-protein IgG at day 43 ; 2) Adverse Events (AEs) within 7 days after each vaccine dose, and the frequency and severity of any AE, with attention to serious AEs (SAE), AE of special interest (AESI) and medically attended AEs (MAAE), throughout the duration of the study

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.